Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (111-120 of 169) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|May 6, 2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3Stefan Zeuzem, Geoffrey M Dusheiko, Riina Salupere, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.
JAMA|July 20, 2014
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfectionMark S Sulkowski, Susanna Naggie, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|October 6, 2020
Precise Definition of a "Monolayer Point" in Polymer Brush Films for Fabricating Highly Coherent TiO<sub>2</sub> Thin Films by Vapor-Phase InfiltrationRoss Lundy, Pravind Yadav, Nadezda Prochukhan, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Pageof 17

Showing results (111-120 of 169) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|May 6, 2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3Stefan Zeuzem, Geoffrey M Dusheiko, Riina Salupere, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.
JAMA|July 20, 2014
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfectionMark S Sulkowski, Susanna Naggie, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|October 6, 2020
Precise Definition of a "Monolayer Point" in Polymer Brush Films for Fabricating Highly Coherent TiO<sub>2</sub> Thin Films by Vapor-Phase InfiltrationRoss Lundy, Pravind Yadav, Nadezda Prochukhan, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Pageof 17